On September 23, 2019 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") reported that a poster highlighting Iomab-B, its pivotal Phase 3 targeted conditioning candidate, was awarded Honorable Distinction at the 2019 SOHO (Society of Hematologic Oncology) Annual Meeting (Press release, Actinium Pharmaceuticals, SEP 23, 2019, View Source [SID1234539688]). SOHO is the only international society specific to the field of hematologic oncology and has grown to over 3,000 members. This year’s SOHO annual meeting was attended by nearly 1,400 physicians, nurses and healthcare professionals and nearly four hundred abstracts and posters were presented including over 70 focused on AML or acute myeloid leukemia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Benjamin Tomlinson, M.D., Assistant Professor, Adult Hematologic and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center (Cleveland, OH) and lead author of the poster, said, "It is an honor for our work to be recognized by SOHO’s scientific committee from the significant number of posters and abstracts that were submitted. The AML therapeutic landscape has evolved rapidly in recent years with eight therapies gaining approval since 2017 including targeted agents like Bcl-2, FLT3 and IDH inhibitors. While these therapies are important advancements for patients with AML, they are not curative, and bone marrow transplant remains the only curative treatment option for patients with active relapsed or refractory AML. Iomab-B is highly differentiated as a targeted agent with a strong anti-leukemic effect as we have demonstrated in this poster selected by SOHO and targeted conditioning ability that led to all patients receiving Iomab-B achieving successful bone marrow transplant and engraftment. These findings are highly encouraging as I am not aware of any other agents that offer such a high probability of bone marrow transplant for this patient population. I look forward to continuing to participate in the SIERRA study and am excited for additional data in the future."

Mark Berger, M.D., Actinium’s Chief Medical Officer, said, "This Honorable Distinction award from SOHO adds to the growing recognition for Iomab-B’s value proposition as the only late-stage targeted conditioning agent for the older relapsed or refractory AML patient population. Since achieving twenty-five percent enrollment and making important changes to the trial protocol, including adding targeted therapies like venetoclax as options in the control arm and reducing the time to crossover evaluation to fourteen days, we have seen a dramatic increase in physician interest and enthusiasm for the SIERRA trial. This groundswell of interest continued to build after preliminary data from the first twenty-five percent of patients was presented in an oral presentation at the ASH (Free ASH Whitepaper) annual meeting in 2018 and a late-breaking oral presentation at the TCT annual meeting in February 2019. These data demonstrated Iomab-B’s ability to enable transplant universally, with deep donor chimerism and no non-relapse mortality at one hundred days post-transplant in the Iomab-B arm. Additionally, Iomab-B’s ability as a single agent to rapidly deplete all circulating leukemic blasts prior to transplant has drawn strong recognition from the medical community, as evidenced by this award from SOHO. These data gained widespread visibility throughout the transplant and hematology communities and as a result, we have seen new sites come into the SIERRA trial bringing us to twenty sites in total at present. There has also been significant physician engagement, which drove us powerfully past fifty-percent enrollment. With the important fifty percent enrollment milestone achieved, we look forward to completing the SIERRA study and further demonstrating Iomab-B’s value proposition at future medical meetings."

The poster presented at SOHO highlighted Iomab-B’s ability as a single agent activity to rapidly deplete peripheral blasts leading to lower circulating leukemia tumor burden prior to BMT, which is critical for successful engraftment. It was observed that a single therapeutic infusion of Iomab-B resulted in a median reduction of peripheral blasts of 98% by day 3 and 100% reduction by day 8 following administration and prior to any other pre-BMT conditioning in the sixteen patients who were evaluated. Rapid reduction of peripheral blasts has been observed as an independent prognostic marker that is predictive of both CR or Complete Response and RFS or Relapse-Free Survival in patients with AML after receiving cytotoxic chemotherapy. Gianfaldoni et al1 performed an analysis of 30 newly diagnosed AML patients who were treated with cytotoxic induction chemotherapy and found that a rapid reduction of peripheral leukemia blasts correlated with responses and all patients that achieved CR had a rapid reduction of their peripheral blasts. Elliot et al2, performed a retrospective analysis of 86 adult patients with AML and identified time to clearance of circulating leukemia blasts as an independent prognostic marker of RFS that superseded all other known risk factors including karyotype and number of cycles of induction therapy needed to achieve CR. As previously presented, all patients receiving Iomab-B in the SIERRA trial, including cross over patients, received a BMT and achieved engraftment without delay.

The poster selected by SOHO for honorable distinction can be viewed on Actinium’s website (here) or the SOHO Annual Meeting website (here).

About the Society of Hematologic Oncology
The Society of Hematologic Oncology (SOHO) is an international society designed specifically for clinicians, research scientists and related healthcare professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to promote worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field. The 2019 SOHO Annual Meeting took place September 11-14 in Houston, Texas, with attendance from nearly 1,400 hematologic oncology professionals from across the globe. Nearly 400 abstracts were accepted for oral or poster presentation at the Annual Meeting. Published abstracts are available through the official journal of the Society, ‘Clinical Lymphoma, Myeloma and Leukemia,’ published by Elsevier. Online access is open to the public at View Source(19)X0009-9 through December 31, 2019. For more information about the Society or to sign-up for FREE membership, go to the official website at View Source

About Iomab-B
Iomab-B is an ARC or Antibody Radiation-Conjugate comprised of the anti-CD45 antibody apamistamab and the radioisotope iodine-131 that is intended to be a targeted conditioning agent prior to a BMT or bone marrow transplant. Iomab-B was developed at the Fred Hutchinson Cancer Research Center and has been studied in over 300 patients in multiple hematologic indications across 12 clinical trials in addition to the ongoing SIERRA study in older patients with active, relapsed or refractory AML or Acute Myeloid Leukemia prior to patients receiving an allogeneic BMT or bone marrow transplant. Iomab-B is Actinium’s lead targeting conditioning ARC in its multi-target, multi-indication targeted conditioning pipeline that includes the Iomab-B and Actimab-MDS programs for BMT and the Iomab-ACT program that will study a lower dose of Iomab-B for lymphodepletion prior to CAR-T and other cellular therapies.